Mar 24, 2025 08:01AM
Mar 24, 2025 08:00AM
Mar 17, 2025 08:00AM
Mar 17, 2025 08:00AM
Mar 13, 2025 08:33AM
Mar 13, 2025 08:30AM
Mar 6, 2025 08:00AM Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
Mar 3, 2025 08:01AM
Mar 3, 2025 08:00AM
Feb 26, 2025 08:00AM
Feb 24, 2025 08:00AM
Feb 6, 2025 08:01AM
Feb 6, 2025 08:00AM
Jan 30, 2025 08:06AM Allarity Therapeutics (ALLR) Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
Jan 30, 2025 08:00AM
Nov 18, 2024 08:03AM
Nov 18, 2024 08:00AM
Nov 14, 2024 08:00AM
Oct 22, 2024 08:00AM
Oct 22, 2024 08:00AM
Oct 10, 2024 08:00AM Allarity Therapeutics (ALLR) Regains Compliance with NASDAQ Minimum Bid Price Requirement
Oct 10, 2024 08:00AM
Oct 3, 2024 08:00AM
Sep 16, 2024 08:00AM
Sep 16, 2024 08:00AM
Sep 11, 2024 08:00AM
Sep 11, 2024 08:00AM
Jul 26, 2024 09:00AM Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
Jul 24, 2024 06:02AM
Jul 24, 2024 06:00AM
Jul 22, 2024 06:32AM
Jul 22, 2024 06:30AM
Jun 27, 2024 08:01AM
Jun 27, 2024 08:00AM
Jun 25, 2024 08:00AM Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
May 20, 2024 08:02AM
May 20, 2024 08:00AM
May 20, 2024 08:00AM
May 20, 2024 08:00AM
May 14, 2024 04:01PM
May 7, 2024 09:30AM
May 6, 2024 08:00AM Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
May 2, 2024 08:03AM
May 2, 2024 08:00AM
Apr 29, 2024 07:02AM
Apr 29, 2024 07:00AM
Apr 17, 2024 09:17AM
Apr 17, 2024 09:10AM
Apr 17, 2024 09:10AM Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
Apr 8, 2024 06:01AM

64,524 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All